Molbio Diagnostics Limited share price

Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.

• Molbio Diagnostics Limited is in the Medical Devices industry (Healthcare), with a market value of ₹18,143 crore.
• It trades at 108.9 times its last 12 months' earnings and 15.2 times book value.
• Revenue grew 63.7% a year over the last 3 years.
• Return on equity was 15.6% and return on capital employed 16.5% in the latest year.
• Debt was 0.38 times shareholders' equity.
• The share price is 6.7% below its 52-week high.
• Promoters and insiders hold about 80.8%; institutions about 9.5%.

Molbio Diagnostics Limited, a point-of-care diagnostics company, provides healthcare technologies to diagnose infectious and non-communicable diseases. It manufactures and sells chip based diagnostic devices, chips and reagents, X-ray equipment's, and single/dual detectors. It also offers disposable POCT devices, which includes dengue, malaria, and COVID-19 tests; Tabletop analysers, a portable machine that are used to perform molecular or immunodiagnostic tests to detect infectious diseases, such as tuberculosis, human papillomavrus, STIs, and GI disorders. In addition, the company offers Truenat, a multi-disease real-time polymerase chain reaction platform that enables treatment decisions for various infectious and non-communicable diseases, such as tuberculosis, human immunodeficiency virus, malaria, viral hepatitis, COVID-19, dengue, chikungunya, influenza, H1N1, HPV/cervical cancer…

Employees

1,225

Head office

Verna

HealthcareMedical Devices

Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.

Consolidated figures in ₹ crore / View Standalone

Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Latest quarter on the right.

Consolidated figures in ₹ crore, as at 31 March

Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.

Consolidated figures in ₹ crore, financial years ending March

Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.

Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.

Numbers in percentages · as filed with NSE each quarter

Source: shareholding patterns filed by the company with NSE. Public = non-institutional holders. Tap a row marked + for its breakdown.

Filings made by the company with NSE; documents open on NSE's website.

Ex-dividend date

1 Jan 1970

Latest quarter

30 Jun 2026

Financial year end

31 Mar 2026

Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.